anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
Compass Therapeutics · pitchdeck

Compass Therapeutics | Investor Presentation Deck | 40 slides

40 pages · 4 arc beats · 2 loops

Pitchdeck Download JSON
Unlock

Compass Therapeutics | Investor Presentation Deck | 40 slides

Compass Therapeutics · 2023-02
arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
SETUP TENSION ANALYSIS EVIDENCE RESOLUTION APPENDIX
HOVER FOR DETAILS · CLICK A SLIDE FOR FULLSCREEN · STEP 2
— No image bound to this slide. Wire up imgproxy to display the rendered slide JPEG.
—

Deck intelligence map

4
coverage by narrative range · generated from this deck JSON
Narrative range 15 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 3 slides 100% 3/3 slides 100% 3/3 slides · 17 hits
— 0/3 slides
— 0/3 slides
33.3% 1/3 slides 100% 3/3 slides · 4 hits 100% 3/3 slides Solution 8 slides 100% 8/8 slides 100% 8/8 slides · 38 hits
— 0/8 slides
50% 4/8 slides
— 0/8 slides
100% 8/8 slides 100% 8/8 slides · 16 hits Market Size 3 slides 100% 3/3 slides 100% 3/3 slides · 12 hits
— 0/3 slides
100% 3/3 slides · 4 hits 33.3% 1/3 slides 100% 3/3 slides 100% 3/3 slides · 6 hits Team 1 slides 100% 1/1 slides 100% 1/1 slides · 9 hits
— 0/1 slides
— 0/1 slides
— 0/1 slides
100% 1/1 slides · 2 hits 100% 1/1 slides

Slide inventory

40
every slide · same image gating as the playbook
01
Slide 1
Features a molecular visualization with a target reticle.front_matter
Open slide detail
02
other
Open slide detail
03
The slide uses a ribbon-style list format to categorize key company information.summarize
Open slide detailBeat · ProblemLoop · Cost Of Inaction
04
The chart uses a horizontal bar format to represent the development stage of various drug candidates.plan_implementation
Open slide detailBeat · ProblemLoop · Cost Of Inaction
05
The slide uses a grid layout to display headshots, names, titles, and a collection of logos representing past or associated company experience.other
Open slide detailBeat · ProblemLoop · Cost Of Inaction
06
The slide features a compass-like icon, suggesting a navigational or strategic focus for the upcoming section.transition
Open slide detailLoop · Cost Of Inaction
07
The slide illustrates the mechanism of action of a bispecific antibody targeting DLL4 and VEGF-A.present_solution
Open slide detailBeat · SolutionLoop · Cost Of Inaction
08
inspire_vision
Open slide detailBeat · SolutionLoop · Cost Of Inaction
09
MTD = Maximum Tolerated Dose; PR = Partial Response; RECIST = Response Evaluation Criteria in Solid Tumors; ORR = Objective Response Rate.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
10
The chart displays tumor growth percentages for individual patients, categorized by cancer type (Gastric, CRC, Other) and labeled with dosage (mpk).show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
11
The table highlights Partial Response (PR) rates with a red border.analyze_data
Open slide detailBeat · SolutionLoop · Cost Of Inaction
12
The chart highlights a subset of patients with significant tumor reduction (boxed area).show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
13
Includes footnotes regarding clinical trial context for hypertension and cytopenia.analyze_data
Open slide detailBeat · SolutionLoop · Cost Of Inaction
14
The slide presents clinical efficacy data comparing monotherapy vs combination therapy across two metrics.show_traction
Open slide detailBeat · SolutionLoop · Cost Of Inaction
15
The slide illustrates a standard Simon 2-Stage design, a common statistical framework for Phase II oncology trials.present_framework
Open slide detailLoop · Cost Of Inaction
16
The table highlights patient age, gender, ECOG status, prior therapies, and cancer subtypes.analyze_data
Open slide detailLoop · Cost Of Inaction
17
This is a standard oncology 'swimmer's plot' or 'waterfall plot' used to demonstrate clinical efficacy.show_traction
Open slide detailLoop · Cost Of Inaction
18
Standard clinical trial swimmer plot visualization.analyze_data
Open slide detailLoop · Cost Of Inaction
19
Includes patient enrollment status and breakdown of ORR by prior lines of therapy.show_traction
Open slide detailLoop · Cost Of Inaction
20
Standard clinical trial survival analysis charts (Kaplan-Meier) with 'Number at risk' tables below.analyze_data
Open slide detailLoop · Cost Of Inaction
21
The slide compares clinical trial data for a specific combination therapy against historical label data for individual components.compare_peers
Open slide detailLoop · Cost Of Inaction
22
The table compares a small sample size (N=24) against much larger historical cohorts.compare_peers
Open slide detailLoop · Cost Of Inaction
23
The slide uses a side-by-side comparison to highlight the superior ORR, PFS, and OS of CTX-009 compared to historical benchmarks like FOLFOX and TOPAZ-1.compare_peers
Open slide detailLoop · Cost Of Inaction
24
The slide outlines a 2:1 randomized clinical trial structure for a drug combination (CTX-009 + Paclitaxel) versus a control (Paclitaxel).plan_implementation
Open slide detailLoop · Cost Of Inaction
25
The slide uses a table for market sizing and a structured layout to contrast 1L and 2L treatment options.size_opportunity
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
26
The slide depicts a standard Simon 2-stage design, a common statistical framework in oncology clinical trials.present_framework
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
27
The slide provides epidemiological data alongside a clinical treatment landscape overview.size_opportunity
Open slide detailBeat · Market SizeLoop · Cost Of Inaction
28
The slide uses a three-column layout to represent sequential or parallel development tracks.plan_implementation
Open slide detailLoop · Cost Of Inaction
29
transition
Open slide detailLoop · Cost Of Inaction
30
Includes a molecular visualization showing the binding site of CTX-471 compared to other antibodies.present_solution
Open slide detailLoop · Cost Of Inaction
31
The slide uses a before-and-after visual comparison of CT scans to demonstrate drug efficacy.show_traction
Open slide detailLoop · Cost Of Inaction
32
plan_implementation
Open slide detailLoop · Cost Of Inaction
33
transition
Open slide detailLoop · Cost Of Inaction
34
The slide uses a process flow diagram to show the transition from testing bispecific formats to the identification of the lead candidate CTX-8371.present_solution
Open slide detailLoop · Cost Of Inaction
35
The slide uses a visual comparison framework to contrast standard therapy (left) with the company's proprietary mechanism (right).present_solution
Open slide detailLoop · Cost Of Inaction
36
The slide shows tumor volume reduction over time, percentage tumor growth inhibition, and individual tumor response curves, highlighting CTX-8371's efficacy.show_traction
Open slide detailLoop · Cost Of Inaction
37
The slide outlines the current progress and future clinical trial design for a drug candidate.plan_implementation
Open slide detailLoop · Cost Of Inaction
38
front_matter
Open slide detailLoop · Cost Of Inaction
39
The slide uses a list-based structure to summarize drug development progress across three distinct assets.summarize
Open slide detailLoop · Cost Of Inaction
40
The timeline uses blue and red color coding for different drug programs or status types.plan_implementation
Open slide detailLoop · Cost Of Inaction